Evaxion A (EVAX) Income towards Parent Company (2020 - 2026)
Evaxion A posted quarterly Income towards Parent Company of -$3.6 million for Q1 2026, down 129.68% year-on-year from $12.2 million in Q1 2025, and up 38.68% on a QoQ basis from -$5.9 million in Q4 2025.
Evaxion A (EVAX) has 7 years of Income towards Parent Company data on file, last reported at -$3.6 million in Q1 2026.
- For the quarter ending Q1 2026, Income towards Parent Company fell 129.68% year-over-year to -$3.6 million; the trailing twelve-month figure through Mar 2026 stood at -$10.2 million (up 26.13% YoY), and the FY2025 full-year result was -$7.7 million, up 27.07% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$3.6 million, up from -$5.9 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at $4.6 million in Q3 2025 and bottomed at -$25.3 million in Q2 2022.
- The 5-year median for Income towards Parent Company is -$5.9 million (2025), against an average of -$5.9 million.
- Peak annual rise in Income towards Parent Company reached 338.66% in 2025, while the deepest fall reached 232.33% in 2025.
- A 5-year view of Income towards Parent Company shows it stood at -$7.2 million in 2022, then jumped by 32.43% to -$4.9 million in 2023, then increased by 25.59% to -$3.6 million in 2024, then plunged by 63.08% to -$5.9 million in 2025, then jumped by 38.68% to -$3.6 million in 2026.
- The last three Income towards Parent Company figures came in at -$3.6 million (Q1 2026), -$5.9 million (Q4 2025), and $4.6 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Revolution Medicines | 32.39 Bn | 32.39 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.63 Mn |
| Dec 31, 2025 | -5.92 Mn |
| Sep 30, 2025 | 4.62 Mn |
| Jun 30, 2025 | -5.22 Mn |
| Mar 31, 2025 | -1.58 Mn |
| Dec 31, 2024 | -3.63 Mn |
| Sep 30, 2024 | -1.94 Mn |
| Jun 30, 2024 | -6.60 Mn |
| Mar 31, 2024 | 1.19 Mn |
| Dec 31, 2023 | -4.88 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -8.67 Mn |
| Mar 31, 2023 | -13.20 Mn |
| Dec 31, 2022 | -7.22 Mn |
| Sep 30, 2022 | -6.09 Mn |
| Jun 30, 2022 | -25.27 Mn |
| Mar 31, 2022 | -6.29 Mn |
| Dec 31, 2021 | -5.72 Mn |
| Sep 30, 2021 | -6.10 Mn |
| Jun 30, 2021 | -8.16 Mn |
| Mar 31, 2021 | -4.91 Mn |
| Dec 31, 2020 | -5.28 Mn |
| Sep 30, 2020 | -5.17 Mn |
| Jun 30, 2020 | -4.23 Mn |
| Mar 31, 2020 | -3.46 Mn |